Health  Vol.6 No.14 , July 2014
Factors Related to Adherence with Treatment of Dyslipidemic Patients on Continuous Use of Oral Lipid-Lowering Drugs
Abstract: Several studies have shown that regular prescribed statins may reduce cardiovascular events and decrease the overall mortality. The aim of this study was to analyze factors related to medication and patients with dyslipidemia, statin users in the city of Ribeirão Preto, São Paulo, Brazil. It was an observational, descriptive, traverse character, relating to the year 2007. We included 332 individuals, randomly selected, of both sexes, referred to public health system and private clinics. The selected individuals were submitted to an interview and their medical files analyzed. Simvastatin was the most frequently used oral lipid-lowering drugs. 60% of patients showed forgetfulness as the main cause for treatment interruption, followed by the difficulty of finding of drugs in public pharmacies. Adherence to diet was the main conduct adopted by patients to help control lipid levels. The prevalent adverse events were muscle cramps, paresthesias of the limbs and muscle pains. Among the key factors that would discourage the correct follow-up treatment for lipid control were: long wait for office visits and the difficulties of finding of drugs in pharmacies (Clinical Hospital of the Faculty of Medicine of Ribeirão Preto-USP and public health posts). The study allowed a reflection regarding the functioning of the Public Health System. The study allows a reflection regarding the functioning of the Public Health System for which we must constantly search for strategies that enable the same functionality, which has factors that discourage patient adherence to treatment.
Cite this paper: Marsola, A. and Cesarino, E. (2014) Factors Related to Adherence with Treatment of Dyslipidemic Patients on Continuous Use of Oral Lipid-Lowering Drugs. Health, 6, 1694-1699. doi: 10.4236/health.2014.614201.

[1]   Brasil, Ministério da Saúde, Secretaria Executiva (2002) A Saúde no Brasil: Estatísticas Essenciais. Estatística e Informação para Saúde, 22, 1990-2000.

[2]   Fonseca, F.A.H. and Follador, W. (2003) Farmacoeconomia e as Vastatinas na Doença Cardiovascular. Revista Brasileira de Medicina, 60, 357-363.

[3]   Martinez, T.L.R., et al. (2003) Campanha Nacional de Alerta Sobre o Colesterol Elevado. Determinação do Nível de Colesterol de 81.262 Brasileiros. Arquivos Brasileiros de Cardiologia, 80, 635-638.

[4]   Martinez, T.L.R. (2003) Manual de Condutas Clínicas em Dislipidemias. Medline Editora, Rio de Janeiro, 35.

[5]   Vaughan, C.J., Murphy, M.B. and Buckley, B.M. (1996) Statins Do More than Just Lower Cholesterol. The Lancet, 348, 1079-1082.

[6]   Freeman, W.M. (2006) Statins, Cholesterol, and the Prevention of Coronary Heart Disease. The Federation of American Societies for Experimental Biology Journal, 20, 200-201.

[7]   Mennickent, S.C., et al. (2008) Efectos Pleiotrópicos de las Estatinas. Revista Médica del Chile, 136, 775-782.

[8]   Instituto Brasileiro de Geografia e Estatística (IBGE).

[9]   Xavier, H.T. (2004) Manual de Dislipidemias e Cardiometabolismo, Ed. BBS, São Paulo, 215.

[10]   Bukkapatnam, R.N., Gabler, N.B. and Lewis, W.R. (2004) Statins for Primary Prevention of Cardiovascular Mortality in Women: A Systematic Review and Meta-Analysis. Preventive Cardiology, 13, 84-90.

[11]   Pasternak, R.C., et al. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Journal of the American College of Cardiology, 40, 567-572.

[12]   Paniz, V.M.V., et al. (2008) Acesso a Medicamentos de uso Contínuo em Adultos e Idosos nas Regiões Sul e Nordeste do Brasil. Caderno de Saúde Pública, 24, 267-680.

[13]   Aziz, M.M., et al. (2011) Prevalência e Fatores Associados ao Acesso a Medicamentos pela População Idosa em uma Capital do sul do Brasil: Um Estudo de Base Populacional. Caderno de Saúde Pública, 27, 1939-1950.